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Background
In psoriatic arthritis (PsA), nail disease is intimately
linked to the presence of DIP joint enthesitis and arthri-
tis. Nail disease has been shown in clinical trials to
respond to treatment with TNF inhibitors. We used
high resolution MRI to assess whether improvements in
psoriasis-related nail disease correlated to improvements
in associated DIP joint enthesitis, osteitis and synovitis
during TNF inhibitor therapy.
Methods
Nine patients with psoriatic nail disease in addition to
active skin or joint involvement were recruited prior to
the commencement of TNF inhibitor therapy. All patients
were TNF inhibitor naive at baseline. Assessments at base-
line and six months included: clinical assessment,
ultrasound of the nails and peripheral entheses and high
resolution MRI scanning of one finger. Peripheral ultra-
sound enthesopathy was scored according to inflammatory
and chronic findings, with the sonographer blinded to dis-
ease state. DIP joint MRI scans were scored by blinded
paired analysis by two musculoskeletal radiologists.
Results
The mean patient age was 39, 2/9 patients were female.
Seven patients had co-existent PsA, of whom all had DIP
involvement. TNF prescription was made according to
NICE guidelines. Five patients received etanercept and
four adalimumab. One psoriasis patient was withdrawn at
five months due to skin non-response. The results are pre-
sented here for the eight patients who completed the
study.
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Table 1
Baseline Six months
Clinical assessment PASI 5.25 0.76
mNAPSI 26 7
Swollen joint count 11 1
Tender joint count 11 1
SPARCC enthesitis index 3.1 0.4
Peripheral entheseal ultrasound assessment Total peripheral enthesopathy ultrasound score 27.8 21.6
Inflammation score related to power Doppler changes 1.0 0.1
Chronic enthesopathy score 11.8 9.9
Clinical and ultrasound assessments, all reported as mean. Arthritis outcome measures reported for PsA patients only.
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Marked improvements were seen in clinical parameters
(skin, joints and nails) as well as peripheral entheseal ultra-
sound assessments (Table 1). Baseline MRI scans showed
DIP enthesitis, osteitis or synovitis in all PsA patients.
Follow-up MRI scans showed persistent inflammatory
changes in the DIP joint, distal phalanx and the soft tissues
around the nail.
Conclusions
In keeping with RCT data, a good clinical response for
arthritis, skin and nail disease was seen with anti-TNF
therapy in patients with psoriatic nail disease. This
exploratory imaging study however shows persistent
ongoing subclinical inflammation (osteitis, synovitis and
enthesopathy) at six months. This could relate to either
a time lag in imaging improvement or the sensitivity of
the imaging techniques used.
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